These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 22941767

  • 21. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [Abstract] [Full Text] [Related]

  • 23. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L.
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [Abstract] [Full Text] [Related]

  • 29. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors.
    Shimabuco AY, Gonçalves CR, Moraes JCB, Waisberg MG, Ribeiro ACM, Sampaio-Barros PD, Goldenstein-Schainberg C, Bonfa E, Saad CGS.
    Adv Rheumatol; 2018 Dec 04; 58(1):40. PubMed ID: 30657103
    [Abstract] [Full Text] [Related]

  • 30. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y, Park S, Kim HS.
    Clin Rheumatol; 2018 Dec 04; 37(12):3275-3284. PubMed ID: 30251059
    [Abstract] [Full Text] [Related]

  • 31. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
    Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C.
    Rheumatology (Oxford); 2013 Oct 04; 52(10):1914-9. PubMed ID: 23878312
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
    Heinonen AV, Aaltonen KJ, Joensuu JT, Lähteenmäki JP, Pertovaara MI, Romu MK, Hirvonen HE, Similä AK, Blom ML, Nordström DC.
    J Rheumatol; 2015 Dec 04; 42(12):2339-46. PubMed ID: 26472421
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.
    Arthritis Res Ther; 2011 Jun 20; 13(3):R94. PubMed ID: 21689401
    [Abstract] [Full Text] [Related]

  • 37. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J, ARTIS Study Group, For the DANBIO Study Group.
    Ann Rheum Dis; 2017 Jan 20; 76(1):105-111. PubMed ID: 27147709
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A, Scherer A, Weber U, Exer P, Bernhard J, Tamborrini G, Riek M, Müller RB, Weiss B, Nissen MJ, Kissling R, Michel BA, Finckh A, Rheumatologists of Swiss Clinical Quality Management Program for Axial Spondyloarthritis.
    Ann Rheum Dis; 2016 Mar 20; 75(3):532-9. PubMed ID: 25667205
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.